Study wrapper · #930

GIPR:GCGR co-agonism restores normal weight in obese rodents.

Perez-Tilve D, Zhang F, Zhang Y, et al. Molecular metabolism. 2026.

DOI: 10.1016/j.molmet.2026.102365PubMed: 41997446

Weak / noneAnimal (in vivo)Mentions: Retatrutide

Editor's note

This is preclinical rodent research where retatrutide serves as a benchmark comparator to a new GLP-1-sparing co-agonist. It offers a mechanistic signal that weight reduction can occur without GLP-1 activity, potentially reducing gastrointestinal effects, but findings are animal-only and early. Retatrutide is central to the comparison rather than the novel agent tested.

Plain-language abstract

In obese mice and rats, a GIPR/GCGR co-agonist reduced excess body weight comparably to retatrutide, which normalized weight even in mice lacking the GLP-1 receptor.

Mixed